---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-017437"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:43:43.797582+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharmaceuticals receives Nasdaq minimum bid price deficiency notice; 180-day cure period

## Summary
- Stock closed below $1.00 for 31 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) deficiency.
- Company has until August 25, 2025 to regain compliance by closing at $1.00 or higher for 10 consecutive business days.
- If compliance not met, Company may seek a second 180-day period via a reverse stock split if other listing standards are met.
- No immediate effect on listing; stock continues trading on Nasdaq Capital Market under symbol 'ACXP'.
- Company intends to monitor bid price and consider available options but can provide no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001104659-25-017437
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465925017437/0001104659-25-017437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465925017437/tm257571d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-017437
- JSON: https://secwatch.observer/filing/0001104659-25-017437.json
- Plain text: https://secwatch.observer/filing/0001104659-25-017437.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.